{"organizations": [], "uuid": "2756330499289becf942c397e41de302f7e7a162", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "finance.yahoo.com", "main_image": "http://l3.yimg.com/bt/api/res/1.2/M7vS95b2fvSzHFeFStPk0A--/YXBwaWQ9eW5ld3NfbGVnbztxPTc1O3c9NjAw/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "http://finance.yahoo.com/rss/headline?s=NVS", "section_title": "Yahoo! Finance: NVS News", "url": "http://finance.yahoo.com/news/glaxosmithkline-3q15-earnings-expect-182718534.html", "country": "US", "title": "GlaxoSmithKline’s 3Q15 Earnings: What Should You Expect? - Yahoo", "performance_score": 0, "site": "yahoo.com", "participants_count": 1, "title_full": "GlaxoSmithKline’s 3Q15 Earnings: What Should You Expect? - Yahoo Finance", "spam_score": 0.0, "site_type": "news", "published": "2015-10-16T03:00:00.000+03:00", "replies_count": 0, "uuid": "2756330499289becf942c397e41de302f7e7a162"}, "author": "Mike Benson", "url": "http://finance.yahoo.com/news/glaxosmithkline-3q15-earnings-expect-182718534.html", "ord_in_thread": 0, "title": "GlaxoSmithKline’s 3Q15 Earnings: What Should You Expect? - Yahoo", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Analyzing Expectations for GlaxoSmithKline's 3Q15 Earnings \nA look at GlaxoSmithKline’s 3Q15 earnings GlaxoSmithKline (GSK) is set to release its earnings on October 28, 2015. Analysts estimate an EPS (earnings per share) of 0.39 pounds for 3Q15. The company’s stock has returned nearly -3.0% YTD (year-to-date), while its competitors Sanofi (SNY), Merck (MRK), and Novartis (NVS) returned ~13.9%, -11.0%, and 3.1%, respectively. The Market Vectors Pharmaceutical ETF (PPH) returned ~0.2% during the same period.\nInvestors can find out reviews for other companies on our Pharmaceutical Earnings Overview page .\nKey drivers The company’s key revenue drivers included HIV products in the Pharmaceuticals segment, meningitis vaccines in the Vaccines segment, and Flonase and other oral health products in the Consumer Healthcare segment. The company completed its Novartis transaction in March 2015, and reported a ~7% top-line growth at constant currencies during 2Q15. This was mainly driven by more sales of the products above, partially offset by a few of the established ones, including respiratory products.\n3Q15 revenue estimates Analysts estimate the revenues for 3Q15 to rise by ~8% at 6.13 billion pounds, compared to 5.65 billion pounds for 3Q14. Apart from multiple new product launches, the company focuses on the proper integration of the Vaccines and Consumer Healthcare divisions following a transaction with Novartis in March 2015.\nCompany overview GlaxoSmithKline is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex, the United Kingdom, so it reports its financial results in British pounds. GlaxoSmithKline is a global company with commercial operations in more than 150 countries, engaging more than 100,000 people. It has a wide network of 84 manufacturing sites in 36 countries and large research and development centers in the United Kingdom, the United States, Spain, Belgium, and China. Further details about the company are discussed in GlaxoSmithKline: A Must-Read Overview .\nContinue to Next Part \nBrowse this series on Market Realist: \nPart 2 - Analysts’ Estimates for GlaxoSmithKline’s 3Q15 Revenues Part 3 - GlaxoSmithKline’s 3Q15: Pharmaceuticals Growth Expected Part 4 - GlaxoSmithKline’s 3Q15 Preview: Expectations for Vaccine Business Health Care Industry GlaxoSmithKline earnings per share", "external_links": [], "published": "2015-10-16T03:00:00.000+03:00", "crawled": "2015-10-16T04:40:00.956+03:00", "highlightTitle": ""}